Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553574 | 1.00 | KCNN4 (0.48) | KCNN4LMNAHTTL3MBTL1CYP2C19 | |
| SCHEMBL30553493 | 1.00 | KCNN4 (0.48) | KCNN4LMNAHTTL3MBTL1CYP2C19 | |
| Hydrochloric Acid SCHEMBL3830549 | 0.98 | KCNN4 (0.46) | KCNN4LMNAHTTL3MBTL1CYP2C19 | |
| SCHEMBL6287223 | 0.83 | KCNN4 (0.48) | KCNN4LMNAHTTL3MBTL1CYP2C19 | |
| SCHEMBL9879385 | 0.79 | KCNN4 (0.41) | KCNN4LMNAHTTL3MBTL1CYP2C19 | |
| SCHEMBL27821193 | 0.79 | RAB9A (0.38) | CYP2C19KMT2AALDH1A1 | |
| SCHEMBL14786288 | 0.78 | KCNN4 (0.43) | KCNN4LMNAHTTL3MBTL1CYP2C19 | |
| SCHEMBL10535008 | 0.78 | KDM4E (0.42) | KCNN4LMNAHTTL3MBTL1CYP2C19 | |
| SCHEMBL28685723 | 0.76 | NAPRT (0.44) | KCNN4LMNAHTTL3MBTL1CYP2C19 | |
| SCHEMBL29393902 | 0.76 | NAPRT (0.44) | KCNN4LMNAHTTL3MBTL1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114058655-B | Method for synthesizing (R) -acetamido phenylpropanol by enzyme-chemical one-pot method | 青岛科技大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-110297043-A | A kind of analysis method of 2- methylamino -1- phenyl-1-propanol | 上海医药工业研究院 | 2019-10-01 | — | — | CN | disclosed |
| CN-107630049-B | The biological preparation method of ephedrine | 武汉茵茂特生物技术有限公司 | 2018-09-21 | — | — | CN | disclosed |
| CN-107630049-A | The biological preparation method of ephedrine | 武汉茵茂特生物技术有限公司 | 2018-01-26 | — | — | CN | disclosed |
| WO-2014159251-A2 | INHIBITING NEUROTRANSMITTER REUPTAKE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1724276-A1 | Novel phosphorus-containing prodrugs | Metabasis Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1704138-A1 | PROCESSES FOR THE PREPARATION OF TOMOXETINE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2006-09-27 | — | — | EP | disclosed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006068662-A1 | PROCESSES FOR THE PREPARATION OF TOMOXETINE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
| EP-1634886-A2 | Novel phosphorus-containing prodrug | Metabasis Therapeutics, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-5225585-A | Antidepressants | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1993-07-06 | — | — | US | disclosed |
| EP-0529842-A2 | Production of fluoxetine and new intermediates | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-03-03 | — | — | EP | disclosed |
| US-4041174-A | INJECTING AN ESTER LOCAL ANESTHETIC | ROM-AMER PHARMACEUTICALS, LTD. (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | KCNN4 1064/4885LMNA 3305/4885HTT 4792/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | KCNN4 1064/4885LMNA 3305/4885HTT 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.